Researchers at the Jackson Laboratory have tested an early version of the GenapSys sequencer and found it to have a very low mismatch error rate.
The Redwood, California-based company plans to use the funding to drive the commercial launch of its semiconductor chip-based sequencing-by-synthesis instrument.
The Chromium Connect, designed for pharma workflows and other high-volume customers, is one of several products coming out of 10x's R&D pipeline.
Frederick National Lab and Q2 Solutions have been validating the kit as early users and plan to implement it in their clinical trial services.
Due out in December, the Magnis automated library prep instrument is meant to be an affordable and easy way for researchers to use Agilent's SureSelect kits.
The research-use-only system, which has a list price of $299,000, fits with Thermo Fisher's vision of a future of disseminated implementation of NGS.
The collaborators are developing a sample prep solution for the Mission Bio Tapestri platform and are working on a hematology-focused panel.
The firm is looking to expand its sales internationally, as well as in the consumer-initiated market, but is being conservative with revenue growth estimates.
MGI hopes to ship the sequencer, one of several products it unveiled at the International Conference on Genomics, to early-access partners in early 2020.
The "augmented intelligence" startup applies machine learning and contextual language processing to make sense of multi-omics datasets and inform drug discovery.
Forensic genetic firm Verogen has bought the genetic genealogy site GEDmatch.
Researchers have 3D-printed plastic bunnies that encase the information needed to make more such bunnies in DNA, according to Discover magazine.
Dan Rather, the former CBS Evening News anchor and executive producer of a new documentary, writes at the Guardian that everyone needs to know about CRISPR.
In PNAS this week: analysis of FOXA1 upregulation in ER-positive breast cancer, gene editing to correct recessive dystrophic epidermolysis bullosa, and more.